How and Where Are Drugs Absorbed?

Preclinical Development Handbook: ADME and Biopharmaceutical Properties

Volumn , Issue , 2008, Pages 249-280

  Bermejo, Marival ^a   Gonzalez Alvarez, Isabel ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Active transport or endocytosis; Passive diffusion and facilitated passive diffusion; Receptor mediated endocytosis

Indexed keywords

EID: 66849101978     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249031.ch8     Document Type: Chapter

References (101)

1. Chiou WL. The rate and extent of oral bioavailability versus the rate and extent of oral absorption:clarification and recommendation of terminology. J Pharmacokinet Pharmacodyn 2001;28(1):3-6.
2. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics, 4th ed. Stamford, CT:Appleton & Lange; 1999.
3. Mayerson M. Principles of Drug Absorption. Modern Pharmaceutics edition. New York:Marcel Dekker; 1995.
4. Artursson P. Epithelial transport of drugs in cell culture. I:A model for studying the passive diffusion of drugs over intestinal absorptive(Caco-2) cells. J Pharm Sci 1990;79(6):476-482.
5. Artursson P, Magnusson C. Epithelial transport of drugs in cell culture. II:Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial(Caco-2) cells. J Pharm Sci 1990;79(7):595-600.
6. Artursson P, Ungell AL, Lofroth JE. Selective paracellular permeability in two models of intestinal absorption:cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 1993;10(8):1123-1129.
7. Fagerholm U, Borgstrom L, Ahrenstedt O, Lennernas H. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. J Drug Target 1995;3(3):191-200.
8. Fagerholm U, Nilsson D, Knutson L, Lennernas H. Jejunal permeability in humans in vivo and rats in situ:investigation of molecular size selectivity and solvent drag. Acta Physiol Scand 1999;165(3):315-324.
9. Lennernas H, Ahrenstedt O, Ungell AL. Intestinal drug absorption during induced net water absorption in man;a mechanistic study using antipyrine, atenolol and enalaprilat. Br J Clin Pharmacol 1994;37(6):589-596.
10. Hasselbalch K. Die Berechnung der Wasserstoffzahl des Blutes aus der freien und gebundenen Kohlensäure desselben und die Sauerstoffbindungen des Blutes als Funktion der Wasserstoffzahl. Biochemistry 1916;78:112.
11. Adibi SA. The oligopeptide transporter(Pept-1) in human intestine:biology and function. Gastroenterology 1997;113(1):332-340.
12. Sadee W, Drubbisch V, Amidon GL. Biology of membrane transport proteins. Pharm Res 1995;12(12):1823-1837.
13. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption:a review of fundamentals. J Clin Pharmacol 2002;42(6):620-643.
14. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001;39(3):209-228.
15. Modern Biopharmaceutics. [computer program]. Version 6.03;Amidon GL, Bermejo M. TSRL, Inc; 2003.
16. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16(5):351-380.
17. Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993;82(9):857-872.
18. Oh DM, Amidon GL. Overview of membrane transport. Pharm Biotechnol 1999;12:1-27.
19. Oh DM, Han HK, Amidon GL. Drug transport and targeting. Intestinal transport. Pharm Biotechnol 1999;12:59-88.
20. Kunta JR, Sinko PJ. Intestinal drug transporters:in vivo function and clinical importance. Curr Drug Metab 2004;5(1):109-124.
21. Shin HC, Landowski CD, Amidon GL. Transporters in the GI tract. In Waterbeemd V-d, Lennernäs H, Pirtursson P, Eds. Drug Bioavailability/Estimation of Solubility, Permeability and Absorption. Weinheim, Germany:Wiley-VCH; 2003.
22. Bermejo M, Ruiz-Garcia A. Oral permeability predictions--from in silico to in vivo models. Business Briefing Pharma Tech 2002;175-180.
23. Karlsson J, Ungell A, Grasjo J, Artursson P. P aracellular drug transport across intestinal epithelia:influence of charge and induced water flux. Eur J Pharm Sci 1999;9(1):47-56.
24. Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 1997;14(9):1210-1215.
25. Bermejo M, Merino V, Garrigues TM, et al. Validation of a biophysical drug absorption model by the PATQSAR system. J Pharm Sci 1999;88(4):398-405.
26. Taylor DC, Pownall R, Burke W. The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine;the effect of lipophilicity. J Pharm Pharmacol 1985; 37(4):280-283.
27. Hendriksen BA, Felix MV, Bolger MB. The composite solubility versus pH profile and its role in intestinal absorption prediction. AAPS PharmSci 2003;5(1):E4.
28. Lennernas H. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm Res 1995;12(11):1573-1582.
29. Anderson BW, Levine AS, Levitt DG, Kneip JM, Levitt MD. Physiological measurement of luminal stirring in perfused rat jejunum. Am J Physiol 1988;254(6 Pt 1):G843-G848.
30. Levitt MD, Furne JK, Strocchi A, Anderson BW, Levitt DG. Physiological measurements of luminal stirring in the dog and human small bowel. J Clin Invest 1990;86(5):1540-1547.
31. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996;13(7):963-977.
32. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004;277(1-2):3-9.
33. Fischer V, Einolf HJ, Cohen D. Efflux transporters and their clinical relevance. Mini Rev Med Chem 2005;5(2):183-195.
34. Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug efflux:formulation and food effects. Adv Drug Deliv Rev 2001;50(Suppl 1):S13-S31.
35. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000;12(1):3-12.
36. Kimura T, Higaki K. G astrointestinal transit and drug absorption. Biol Pharm Bull 2002;25(2):149-164.
37. de Vries ME, Bodde HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst 1991;8(3):271-303.
38. Squier CA. The permeability of oral mucosa. Crit Rev Oral Biol Med 1991;2(1):13-32.
39. de Vries ME, Bodde HE, Busscher HJ, Junginger HE. Hydrogels for buccal drug delivery:properties relevant for muco-adhesion. J Biomed Mater Res 1988;22(11):1023-1032.
40. Shojaei AH. Buccal mucosa as a route for systemic drug delivery:a review. J Pharm Pharm Sci 1998;1(1):15-30.
41. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992;81(1):1-10.
42. Galey WR, Lonsdale HK, Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J Invest Dermatol 1976;67(6):713-717.
43. Wertz PW, Squier CA. Cellular and molecular basis of barrier function in oral epithelium. Crit Rev Ther Drug Carrier Syst 1991;8(3):237-269.
44. Squier CA, Cox P, Wertz PW. Lipid content and water permeability of skin and oral mucosa. J Invest Dermatol 1991;96(1):123-126.
45. Chan KK, Gibaldi M. Effects of first-pass metabolism on metabolite mean residence time determination after oral administration of parent drug. Pharm Res 1990;7(1):59-63.
46. Streisand JB, Zhang J, Niu S, McJames S, Natte R, Pace NL. Buccal absorption of fentanyl is pH-dependent in dogs. Anesthesiology 1995;82(3):759-764.
47. Narawane LVHL. Absorption Barriers. Harwood Academic, Switzerland:AG de Boer; 1994.
48. Kurosaki YNH, Terao K, Nakayama T, Kimura T. Existence of specialized absorption mechanism for cephadroxyl, an aminocephalosporin antibiotic, in the human oral cavity. Int J Pharm 1992;82:165-169.
49. Graves NM, Kriel RL. Rectal administration of antiepileptic drugs in children. Pediatr Neurol 1987;3(6):321-326.
50. Roelofse JA, van der Bijl P, Stegmann DH, Hartshorne JE. Preanesthetic medication with rectal midazolam in children undergoing dental extractions. J Oral Maxillofac Surg 1990;48(8):791-797;discussion 797.
51. Malinovsky JM, Lejus C, Servin F, et al. Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. Br J Anaesth 1993;70(6):617-620.
52. Hanning CD. The rectal absorption of opioids. In Benedetti C, Chapman CR, Giron G, Eds. Advances in Pain Research and Therapy. Philadelphia:Lippincott-Raven; 1990; 14:259-268.
53. Alternative routes of drug administration-advantages and disadvantages(subject review). American Academy of Pediatrics. Committee on Drugs. Pediatrics 1997;100(1):143-152.
54. van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration. Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet 1991;21(2):110-128.
55. Choonara IA. Giving drugs per rectum for systemic effect. Arch Dis Child 1987; 62(8):771-772.
56. Khalil SN, Florence FB, Van den Nieuwenhuyzen MC, Wu AH, Stanley TH. Rectal methohexital:concentration and length of the rectal catheters. Anesth Analg 1990; 70(6):645-649.
57. van Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration. Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet 1991;21(1):11-26.
58. Forbes RB, Vandewalker GE. Comparison of two and ten percent rectal methohexitone for induction of anaesthesia in children. Can J Anaesth 1988;35(4):345-349.
59. Jantzen JP, Erdmann K, Witton PK, Klein AM. The effect of rectal pH values on the absorption of methohexital. Anaesthesist 1986;35(8):496-499.
60. Jantzen JP, Tzanova I, Witton PK, Klein AM. Rectal pH In children. Can J Anaesth 1989;36(6):665-667.
61. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 1983;127(5 Pt 2):S59-S65.
62. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002;7(18):967-975.
63. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. P harm World Sci 2004;26(3):137-142.
64. Illum L. Nasal drug delivery:new developments and strategies. Drug Discov Today 2002;7(23):1184-1189.
65. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87(1-3):187-198.
66. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51(1-3):81-96.
67. Chavanpatil MD, Vavia PR. The influence of absorption enhancers on nasal absorption of acyclovir. Eur J Pharm Biopharm 2004;57(3):483-487.
68. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003;42(13):1107-1128.
69. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 2005;60(2):207-225.
70. Hosoya K, Tomi M. Advances in the cell biology of transport via the inner blood-retinal barrier:establishment of cell lines and transport functions. Biol Pharm Bull 2005;28(1):1-8.
71. Reichl S, Dohring S, Bednarz J, Muller-Goymann CC. Human cornea construct HCC-an alternative for in vitro permeation studies? A comparison with human donor corneas. Eur J Pharm Biopharm 2005;60(2):305-308.
72. Kim MK, Lee CH, Kim DD. Skin permeation of testosterone and its ester derivatives in rats. J Pharm Pharmacol 2000;52(4):369-375.
73. Lopez A, Llinares F, Cortell C, Herraez M. Comparative enhancer effects of Span20 with Tween20 and Azone on the in vitro percutaneous penetration of compounds with different lipophilicities. Int J Pharm 2000;202(1-2):133-140.
74. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004;9(16):697-703.
75. Kalia YN, Merino V, Guy RH. Transdermal drug delivery. Clinical aspects. Dermatol Clin 1998;16(2):289-299.
76. Dezarnaulds G, Fraser IS. Vaginal ring delivery of hormone replacement therapy-a review. Expert Opin Pharmacother 2003;4(2):201-212.
77. Buchanan DL, Kurita T, Taylor JA, Lubahn DB, Cunha GR, Cooke PS. Role of stromal and epithelial estrogen receptors in vaginal epithelial proliferation, stratification, and cornification. Endocrinology 1998;139(10):4345-4352.
78. Woolfson AD, Malcolm RK, Gallagher R. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst 2000;17(5):509-555.
79. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril 2004;82(1):1-12.
80. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release 2005;103(2):301-313.
81. van der Bijl P, Van Eyk AD. Comparative in vitro permeability of human vaginal, small intestinal and colonic mucosa. Int J Pharm 2003;261(1-2):147-152.
82. Furness G. Needle-Free and Auto Injectors-Management Forum Conference. An update on technology and application. 23-24 Feb 2004, London, UK. IDrugs 2004;7(4):329-330.
83. Ajmani D. Going from needles to needle-free injectables. Drug Deliv Technol 2004; http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=318
84. Paice JA, Magolan JM. Intraspinal drug therapy. Nurs Clin North Am 1991;26(2):477-498.
85. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption:immediate release dosage forms. Pharm Res 1998;15(1):11-22.
86. Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999;36(1):59-79.
87. Kamm W, Hauptmann J, Behrens I, et al. Transport of peptidomimetic thrombin inhibitors with a 3-amidino-phenylalanine structure:permeability and efflux mechanism in monolayers of a human intestinal cell line(Caco-2). Pharm Res 2001;18(8):1110-1118.
88. Stenberg P, Luthman K, Ellens H, et al. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm Res 1999;16(10):1520-1526.
89. Casabo VG, Nunez-Benito E, Martinez-Coscolla A, Miralles-Loyola E, Martin-Villodre A, Pla-Delfina JM. Studies on the reliability of a bihyperbolic functional absorption model. II. Phenylalkylamines. J Pharmacokinet Biopharm 1987;15(6):633-643.
90. Dowty ME, Dietsch CR. Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra-and inter-rat variability. Pharm Res 1997;14(12):1792-1797.
91. Camenisch G, Folkers G, van de Waterbeemd H. S hapes of membrane permeability-lipophilicity curves:extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci 1998;6(4):325-329.
92. Norinder U, Osterberg T, Artursson P. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 1999;8(1):49-56.
93. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci 1996;85(1):32-39.
94. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999;88(8):815-821.
95. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 1999;88(8):807-814.
96. Roskos KV, Maibach HI. Percutaneous absorption and age. Implications for therapy. Drugs Aging 1992;2(5):432-449.
97. Lotte C, Wester RC, Rougier A, Maibach HI. Racial differences in the in vivo percutaneous absorption of some organic compounds:a comparison between black, Caucasian and Asian subjects. Arch Dermatol Res 1993;284(8):456-459.
98. Gean CJ, Tur E, Maibach HI, Guy RH. Cutaneous responses to topical methyl nicotinate in black, Oriental, and Caucasian subjects. Arch Dermatol Res 1989;281(2):95-98.
99. Kompaore F, Marty JP, Dupont C. In vivo evaluation of the stratum corneum barrier function in blacks, Caucasians and Asians with two noninvasive methods. Skin Pharmacol 1993;6(3):200-207.
100. Tsai JC, Sheu HM, Hung PL, Cheng CL. Effect of barrier disruption by acetone treatment on the permeability of compounds with various lipophilicities:implications for the permeability of compromised skin. J Pharm Sci 2001;90(9):1242-1254.
101. Gould AR, Sharp PJ, Smith DR, et al. Increased permeability of psoriatic skin to the protein, plasminogen activator inhibitor 2. Arch Dermatol Res 2003;295(6):249-254.